Erasca Inc. (ERAS) sees its price target raised from $5 to $12 by Guggenheim, following promising clinical data for its lead oncology candidates and updated financial models. The move comes amid a series of positive analyst revisions for the clinical-stage biopharma firm.
Clinical-stage biopharma Mineralys Therapeutics has filed its New Drug Application for lorundrostat, a potential treatment for resistant hypertension, following positive results from multiple trials. The move positions the company for a potential 2026 market entry and has drawn upgraded price targets from analysts.
Guggenheim Securities has initiated coverage of clinical-stage biopharma AtaiBeckley with a Buy rating and an $11 price target, highlighting its leadership in next-generation psychiatric treatments following its merger with Beckley Psytech.
Clinical-stage biopharma Alumis Inc. (ALMS) is gaining significant Wall Street attention after its lead drug candidate, envudeucitinib, successfully met all endpoints in key Phase 3 trials for plaque psoriasis, prompting multiple analyst upgrades and optimistic price targets.
Immunocore Holdings (NASDAQ: IMCR) has drawn renewed bullish sentiment from analysts at H.C. Wainwright and UBS, who highlight the stock's potential as key Phase 3 trial data for its cancer immunotherapies approaches later this decade.
Bank of America has raised its price target for clinical-stage biopharma firm Xencor (XNCR), highlighting a cautiously improving landscape for the sector driven by data catalysts, M&A, and capital access.
As Insmed prepares to unveil key data for its TPIP program at a major medical congress, fresh analyst coverage highlights the treatment's potential to reshape the company's future. Amidst a volatile stock performance, investors are weighing high-growth prospects against persistent financial risks.
The Qatar Investment Authority has backed a new $200 million fund by Shorooq Partners, aiming to inject institutional capital into the region's mature startups and bridge a critical funding hurdle on the path to public listings.
Quince Therapeutics' lead candidate, eDSP, has failed to meet primary and secondary endpoints in its pivotal Phase III NEAT trial for the rare neurological disorder Ataxia-Telangiectasia (A-T), triggering a catastrophic drop in the company's share price.
Initial drill results from the Senneville gold-silver-copper property in Quebec's prolific Val-d'Or camp have intersected significant near-surface mineralization, with intervals up to 57.8 meters, marking a promising start to the multi-phase exploration campaign.
Iranian opposition figures allege recent state media images of Supreme Leader Khamenei are a calculated display meant to bolster morale within the security apparatus, as the regime confronts domestic unrest and international pressure.
For many companies, shipping remains a blind spot in the budget. New analysis reveals how leveraging logistics data can identify inefficiencies, renegotiate carrier contracts, and transform a cost center into a source of competitive advantage.
President Trump's nomination of former Fed Governor Kevin Warsh to lead the central bank is seen as a pivotal test of its political independence, potentially aligning monetary policy more closely with White House objectives.
BeOne Medicines extends its collaboration with quantitative systems pharmacology firm InSysBio, aiming to optimize clinical trial dosing and mitigate cytokine release syndrome risks across its broad portfolio of 15 novel oncology assets.
With a cash reserve that could last just over a year at its current burn rate, InflaRx faces a critical period to prove its clinical pipeline's value. While management has reined in spending, the company's financial strategy is now under the microscope.
In a bid to boost the global competitiveness of Indian accounting and advisory firms, the government has announced a dual-pronged reform: simplifying the 'accountant' definition under Safe Harbour Rules and merging tax computation standards with financial reporting norms.
BeOne Medicines (NasdaqGS: ONC) has significantly expanded its strategic partnership with systems biology firm InSysBio. The deepened collaboration aims to leverage advanced mechanistic modeling to de-risk clinical trial design, with a particular focus on optimizing dosing and preempting safety challenges like cytokine release syndrome in oncology studies.
Minerals 260 (ASX:MI6) has significantly upgraded the resource estimate at its Bullabulling gold project to 4.5 million ounces, bolstered by strong drilling results and a solid cash position. The expansion shifts focus to the upcoming pre-feasibility study and execution risks as the company targets key development decisions by 2026.
Exelixis has filed its next-generation therapy zanzalintinib with U.S. regulators for metastatic colorectal cancer, marking a significant step in its clinical development and potentially enhancing its competitive position in the targeted oncology space.
Biotech firm Definium Therapeutics appoints seasoned commercial executive Roger Adsett to its board, signaling a strategic shift towards commercialization as key late-stage trial data approaches.
